IAPG Rec'd PCT/PTO 10 FEB 2006

		,	IN O 1				
FORM P	TO-139 2005)	0 (Modified) U.S. PATENT AND TRADEMAR	RK OFFICE; U.S. DEPARTMENT OF COMMERCE	ATTORNEY'S DOCKET NUMBER			
(NE +		ANSMITTAL LETTER TO	PU5028USW				
	Г	DESIGNATED/ELECTED	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)				
<u>ر</u> ا		CERNING A SUBMISSION	10/535,228				
			PRIORITY DATE CLAIMED				
N		PCT/US03/35808	INTERNATIONAL FILING DATE November 12, 2003	November 22, 2002			
	_	NVENTION					
Farne	soid 2	X Receptor Agonists					
			<u> </u>				
		T(S) FOR DO/EO/US	TARROW BALL DATE ON THE PARTIES	5			
BOGG	38, 5	haron, D.; COLLINS, Jon, L.; HY	YATT, Stephen, M.; MALONEY, Patrick	ζ, R .			
^applies	ant he	crowith submite to the United States	Designated/Elected Office (DO/EO/US) the	following items and other information:			
	_						
1.			s concerning a submission under 35 U.S.C.				
2.			NT submission of items concerning a submis				
3.		This is an express request to begin (9) and (24) indicated below.	national examination procedures (35 U.S.U.	371(f)). The submission must include items (5), (6),			
4.		The US has been elected (Article 31	1).				
5.		A copy of the International Application	ion as filed (35 U.S.C. 371 (c)(2))				
		a. is attached hereto (required only if not communicated by the International Bureau).					
ļ.		b. has been communicated by the International Bureau.					
		c. \square is not required, as the app	olication was filed in the United States Recei	iving Office (RO/US).			
6.		An English language translation of t	the International Application as filed (35 U.S	.C. 371(c)(2)).			
		a. is attached hereto.					
		b. has been previously submitted under 35 U.S.C. 154(d)(4).					
7.		Amendments to the claims of the In	nternational Application under PCT Article 19	9 (35 U.S.C. 371 (c)(3))			
		a. are attached hereto (requi	ired only if not communicated by the Interna-	itional Bureau).			
		b. have been communicated	by the International Bureau.				
		c. have not been made; however, the time limit for making such amendments has NOT expired.					
		d. \Box have not been made and v	will not be made.				
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).					
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).					
11.		A copy of the International Preliminary Examination Report (PCT/IPEA/409).					
12.		A copy of the International Search Report (PCT/ISA/210).					
lte	ms 1	3 to 23 below concern document(s	s) or information included:				
13.		An Information Disclosure Stateme	ent under 37 CFR 1.97 and 1.98.				
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
15.		A FIRST preliminary amendment.					
16.		A SECOND or SUBSEQUENT preliminary amendment.					
17.		A substitute specification.					
18.		A power of attorney and/or change of address letter.					
19.	\boxtimes	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.					
20.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).					
21.		A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).					
22.		Express Mail Label No.					
		多上 (1	EMER				

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (if known, see 37 CFR 1.5) INTERNATIONAL APP				APPL	ICATION NO.	ATTORNEY'S DOCKET NUMBER	
1	10/535,228		PCT/USO	3/35	808	PU5028U	sw
23. Other items or information: a) Statement to Support Filing & Submission in Accordance with 37 CFR 1.821-1.825 b) Sequence Listing (hardcopy)							
c) Sequen	ce Listing (on Disk))					
d) Copy o	f Notification to Co	omply w/Req	uirements for Patent A	pplica	tions Containing	Nucleotide and/or Amin	o Acid
The following	r food have been s	ubmittad:				CALCULATIONS	PTO USE
	g fees have been s ational fee				\$300	\$ \$0.00	
25. D Examina	ation fee (37 CFR	1.492(c))					
If the written opin	ion prepared by IS	A/US or the	international prelimina provisions of PCT Art	ry exa		\$ \$0.00	
		•	· · · · · · · · · · · · · · · · · · ·		\$0 \$200		
	fee (37 CFR 1.492		Alanah and Basinana and	-!4!			
by IPEA/US	indicates all clain	ns satisfy pro	itional preliminary exar ovisions of PCT Article	33(1))-(4) \$0		
			on the international ap			\$ \$0.00	:
International Sea	rch Report prepare	ed by an ISA	other than the US and	prov	ided to the		
			∍ IB				
TOTAL	L OF 24, 25 and	26 =				\$ \$0.00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.							
Total Sheets							
- 100 =	0 /50 =		0		× \$250.00	\$ \$0.00	
			earch fee, examinatior the national stage (37			\$	
CLAIMS	NUMBER F	ILED	NUMBER EXTRA		RATE	: 	
Total claims		- 20 =	0	х	\$50.00	\$ \$0.00	
Independent clair	ns	- 3=	0	х	\$200.00	\$ \$0.00	
MULTIPLE DEPE	NDENT CLAIMS	(if applicable	a) 🗆	+	\$360.00	\$ \$0.00	
TOTAL OF ABOVE CALCULATIONS =						\$ \$0.00	
Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.						\$ \$0.00	
				S	UBTOTAL =	\$ \$0.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).						\$ \$0.00	
TOTAL NATIONAL FEE =						\$ \$0.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$ \$0.00	
TOTAL FEES ENCLOSED =					\$ \$0.00		
						Amount to be	\$
						Amount to be	\$

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. to cover the above fees is enclosed. a. A check in the amount of \$ \$0.00 to cover the above fees. Please charge my Deposit Account No. 07-1392 in the amount of \$ A duplicate copy of this sheet is enclosed. c. 🔀 The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment . A duplicate copy of this sheet is enclosed. to Deposit Account No. 07-1392 d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status SEND ALL CORRESPONDENCE TO: SIGNATURE Lorie Ann Morgan NAME 23347 38,181 **REGISTRATION NUMBER**

LAFS COC'O PCT/FTO 10 EEB 2006PCT

CERTIFICATE OF Applicant(s): Boggs et	Docket No. PU5028USW					
Application No. 10/535,228	Filing Date Concurrently Herewith	Examiner	Customer No. 23347	Group Art Unit		
Invention: Farnesoid	X Receptor Agonists					
FEB 1 9 2006		, <u>-</u>				
I hereby certify that t	this Response to Missing	g Requirements (Identify type of correspondence)				
is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on February 7, 300 9						
		Valerie L. (Typed or Printed Name of Person		lence)		
Valerie L. Millin						
		(Signature of Person Mail	ung Correspondence,			
	Note: Each par	per must have its own certificate of mailing.				



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450
Alexandra, Vagnia 2011-1450
www.upto.gov

FIRST NAMED APPLICANT ATTY, DOCKET NO. U.S. APPLICATION NUMBER NO. PU5028USW 10/535.228 Sharon D Boggs

INTERNATIONAL APPLICATION NO. PCT/US03/35808

23347 GLAXOSMITHKLINE CORPORATE INTELLECTUAL PROPERTY, MAI B475 FIVE MOORE DR., PO BOX 13398 RESEARCH TRÍANGLE PARK, NC 27709-3398

PRIORITY DATE I.A. FILING DATE 11/22/2002 11/12/2003

CONFIRMATION NO. 5668

Docket No: PUSO28 USW Attorney: Paper:N(Camp

371 FORMALITIES LETTER *OC000000017718318*

Date Mailed: 01/17/2006

Due Date: 17 Deadline. 17 Recorded:

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

KAREN R MCLEAN

Telephone: (703) 308-9140 EXT 214

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLIC	ATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
. 10	/535,228	PCT/US03/35808	PU5028USW

FORM PCT/DO/EO/922 (371 Formalities Notice)